Plus   Neg

Box Announces KKR-led Investment - Quick Facts

Global investment firm KKR funds will lead a $500 million investment in Box, Inc. (BOX) in the form of convertible preferred stock. The preferred stock will be convertible into shares of Box common stock at a conversion price of $27.00 per share. The preferred stock carries a 3% dividend, which will be payable in kind or in cash, at Box's election. Upon closing of the deal, John Park, Head of Americas Technology Private Equity at KKR, will join Box's Board.

Box anticipates the investment to close in May 2021. The company plans to use substantially all of the proceeds to fund a share repurchase through a "Dutch auction" self-tender of up to $500 million of its common stock.

Box reaffirmed its vision to deliver the Content Cloud and drive profitable growth. The company remains confident to achieve a revenue growth rate between 12-16%, with operating margins of between 23-27%, by fiscal 2024.

Box also announced that current director Bethany Mayer will be appointed as Chair of the Board, effective May 1, 2021. She joined the Board in April 2020 as an independent director.

Shares of Box, Inc. were down 5% in pre-market trade on Thursday.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Walt Disney World, the Orlando, Florida-based entertainment complex, is easing the health safety guidelines that were rolled out to prevent the spread of the ongoing COVID-19 pandemic. The complex is ending temperature checks in a phased manner following the advice of the Centers for Disease Control and Prevention (CDC) and local health officials. Frito-Lay North America, the convenient foods division of food and beverages giant PepsiCo, Inc., is recalling select Ruffles All Dressed Potato Chips citing the possible presence of undeclared milk ingredients, a known allergen, the U.S. Food and Drug Administration said. According to the agency, the recalled products may have distributed regionally to Walmart's Sam's Club Warehouses. Pfizer Inc. (PFE) and BioNTech SE (BNTX) announced Friday that they have initiated the Biologics License Application (BLA) process with the U.S. Food and Drug Administration (FDA) for approval of their mRNA vaccine to prevent COVID-19 in individuals 16 years of age and older. The companies initiated...
Follow RTT